eISSN: 2299-0046
ISSN: 1642-395X
Advances in Dermatology and Allergology/Postępy Dermatologii i Alergologii
Current issue Archive Manuscripts accepted About the journal Editorial board Journal's reviewers Abstracting and indexing Subscription Contact Instructions for authors
SCImago Journal & Country Rank
1/2009
vol. 26
 
Share:
Share:
more
 
 
abstract:

Original papers
New trends in the management of mycosis fungoides and Sezary syndrome

Aleksandra Batycka-Baran
,
Adam Reich
,
Alina Jankowska-Konsur
,
Joanna Maj

Post Dermatol Alergol 2009; XXVI, 1: 41–55
Online publish date: 2009/03/05
View full text
Get citation
ENW
EndNote
BIB
JabRef, Mendeley
RIS
Papers, Reference Manager, RefWorks, Zotero
AMA
APA
Chicago
Harvard
MLA
Vancouver
 
Abstract
Primary cutaneous lymphomas (PCLs) are the most common extranodal non-Hodgkin lymphomas. Given their rich cutaneous symptomatology, frequently ambiguous histology, rarity and heterogeneity, they represent a diagnostic and therapeutic challenge. However, rapid progress of understanding the pathogenesis of these malignancies has been observed recently. Hopefully, this will result in the development of new diagnostic and therapeutic strategies. Here, we review new trends in the diagnostics and therapy of PCL. Particularly rapid progress is observed in mycosis fungoides, the most common T-cell PCL. Based on the newest treatment recommendations for mycosis fungoides, therapy should be started in the early stages. As no curative therapy is currently available, the major goal of treatment is prevention or delay of progression from early disease stages to the later ones. Patients require long-term, sequential therapies with as little toxicity as possible. Skin directed therapy generally produces a good response in the early stages. As the disease progresses, a systemic therapy with immunological modifiers such as bexarotene, interferon a, denileukin diftitox or methotrexate should be applied. Non-responders have to be treated with chemotherapeutic agents, starting with purine analogues and progressing to polychemotherapy. Combined therapy seems to improve response rates, safety and tolerability of treatment. The new therapeutic methods such as histone deacetylase inhibitors, Toll-like receptor agonists, forodesine, third generation adenoviral vector systems, alemtuzumab, zanolimumab are also currently being investigated.
Key words: mycosis fungoides, immunomodulators, primary cutaneous T-cell lymphomas, skin oriented therapy, Sezary syndrome.
keywords:

mycosis fungoides, immunomodulators, primary cutaneous T-cell lymphomas, skin oriented therapy, Sezary syndrome

Quick links
© 2019 Termedia Sp. z o.o. All rights reserved.
Developed by Bentus.
PayU - płatności internetowe